Advanced Therapy Medicinal Products CDMO Market by Products (Cell Therapy, Gene Therapy, Tissue Engineered), Phase (Phase I, Phase II, Phase III), Indication, End-Users - Global Forecast 2024-2030
The Advanced Therapy Medicinal Products CDMO Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.74 billion in 2024, at a CAGR 17.06% to reach USD 22.74 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Advanced Therapy Medicinal Products CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Advanced Therapy Medicinal Products CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..
Market Segmentation & Coverage
This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:
Products
Cell Therapy
Gene Therapy
Tissue Engineered
Phase
Phase I
Phase II
Phase III
Phase IV
Indication
Cardiology
Central Nervous System
Dermatology
Endocrine, Metabolic, Genetic
Gastroenterology
Hematology
Immunology & Inflammation
Infectious Disease
Musculoskeletal
Oncology
Ophthalmology
End-Users
Academic and Research Institutions
Biotechnology & Pharmaceutical Companies
Clinical Research Organizations (CROs)
Hospitals and Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom The report offers valuable insights on the following aspects:
Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
What is the market size and forecast of the Advanced Therapy Medicinal Products CDMO Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Advanced Therapy Medicinal Products CDMO Market?
What are the technology trends and regulatory frameworks in the Advanced Therapy Medicinal Products CDMO Market?
What is the market share of the leading vendors in the Advanced Therapy Medicinal Products CDMO Market?
Which modes and strategic moves are suitable for entering the Advanced Therapy Medicinal Products CDMO Market?
Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Advanced Therapy Medicinal Products CDMO Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel
infectious diseases
5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
5.1.1.3. Increasing investments in pharmaceutical research and development worldwide
5.1.2. Restraints
5.1.2.1. High cost associated with outsourcing ATMP solutions
5.1.3. Opportunities
5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal
products CDMOs
5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
5.1.4. Challenges
5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and
commercialization
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Advanced Therapy Medicinal Products CDMO Market, by Products
6.1. Introduction
6.2. Cell Therapy
6.3. Gene Therapy
6.4. Tissue Engineered
7. Advanced Therapy Medicinal Products CDMO Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
8. Advanced Therapy Medicinal Products CDMO Market, by Indication
8.1. Introduction
8.2. Cardiology
8.3. Central Nervous System
8.4. Dermatology
8.5. Endocrine, Metabolic, Genetic
8.6. Gastroenterology
8.7. Hematology
8.8. Immunology & Inflammation
8.9. Infectious Disease
8.10. Musculoskeletal
8.11. Oncology
8.12. Ophthalmology
9. Advanced Therapy Medicinal Products CDMO Market, by End-Users